Loading clinical trials...

Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors | Clinical Trials | Clareo Health

RECRUITINGPHASE1

Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-T187, an EGFR×MET Trispecific Antibody, Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors

NCT06598800•BeiGene

View on ClinicalTrials.gov

Summary

This is a first-in-human (FIH), Phase 1a/1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-T187 alone and in combination with other therapeutic agents in participants with advanced solid tumors.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Able to provide a signed and dated written informed consent prior to any study-specific procedures, sampling, or data collection.
•2. Participants must be ≥ 18 years of age or the legal age of consent in the jurisdiction in which the study is taking place.
•3. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1.
•4. Participants with selected histologically or cytologically confirmed advanced, metastatic, and unresectable solid tumors who have been previously treated.
•5. ≥ 1 measurable or nonmeasurable lesion as assessed by RECIST v1.1. for Phase 1a Part A; ≥ 1 measurable lesion per RECIST v1.1. for Phase 1a Part B and Phase 1b.
•6. Adequate organ function.

Exclusion Criteria

•1. Prior severe allergic reactions or hypersensitivity to the active ingredient and excipients of BG-T187 or other monoclonal antibodies.
•2. Spinal cord compression, active leptomeningeal disease, or uncontrolled, untreated brain metastasis.
•3. Any malignancy ≤ 3 years before the first dose of study drug(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast).
•4. History of interstitial lung disease (ILD) or noninfectious pneumonitis requiring steroids or other immune suppressive agents ≤ 2 years before the first dose of the study drug, or with current ILD/noninfectious pneumonitis, or where suspected ILD/noninfectious pneumonitis cannot be ruled out by imaging during screening.
•5. Uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage (recurrence ≤14 days after intervention).
•6. Active hepatitis C.
•7. Infection (including tuberculosis infection, or other) requiring systemic (oral or intravenous) antibacterial, antifungal, or antiviral therapy ≤ 14 days before the first dose of study drug(s).

Locations (26)

Hackensack University Medical Center

Hackensack, New Jersey, United States

The University of Texas Md Anderson Cancer Center

Houston, Texas, United States

Next Virginia

Fairfax, Virginia, United States

Washington University, St Louis, Division of Oncology

Madison, Wisconsin, United States

Blacktown Cancer and Haematology Centre

Blacktown, New South Wales, Australia

Macquarie University

North Ryde, New South Wales, Australia

Cabrini Hospital Malvern

Malvern East, Victoria, Australia

Linear Clinical Research

Nedlands, Western Australia, Australia

Cancer Hospital Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China

Chongqing University Cancer Hospital

Chongqing, Chongqing Municipality, China

Key Dates

Start Date

October 18, 2024

Primary Completion Date

September 30, 2028

Completion Date

September 30, 2028

Last Updated

March 12, 2026

Enrollment

ESTIMATED participants

Conditions

Advanced Solid Tumor

Interventions

Drug: BG-T187

DRUG

Other Therapeutic Agents

DRUG

Contacts

Study Director

CONTACT

1.877.828.5568 clinicaltrials@beigene.com

Study Director

CONTACT

A Study of PYX-201 in Advanced Solid Tumors

NCT05720117

Solid TumorAdvanced Solid Tumor

View study

RECRUITINGPHASE1/PHASE2

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

NCT06898450

Advanced Solid Tumors CancerMSI-H Cancer

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 12, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors

Inclusion Criteria

Exclusion Criteria

A Study of PYX-201 in Advanced Solid Tumors

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

A Study of ASP1002 in Adults for Treatment of Solid Tumors

A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combinations in Advanced Solid Tumors

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors